Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingInterventionalPhase 3

Docetaxel Addition in Metastatic Castrate-Sensitive Prostate Cancer (ASPIRE)

NCT ID: NCT06931340Sponsor: Alliance for Clinical Trials in OncologyLast updated: 2026-06-02

Summary

This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Hormone therapy for prostate cancer, also called androgen deprivation therapy (ADT), uses surgery or drugs to lower the levels of male sex hormones in a man's body. This helps slow the growth of prostate cancer. Apalutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of tumor cells. Giving docetaxel in addition to the usual treatment of hormonal therapy and apalutamide may work better in treating patients with metastatic prostate cancer than the usual treatment alone.

Detailed description

PRIMARY OBJECTIVE: I. To determine if the addition of docetaxel to androgen deprivation therapy and apalutamide improves overall survival for men with metastatic castrate sensitive prostate cancer. SECONDARY OBJECTIVES: I. To determine if the addition of docetaxel to androgen deprivation therapy and apalutamide improves overall survival for men whose cancers have loss or inactivating mutations of TP53, PTEN, or RB1. II. To determine if the addition of docetaxel to ADT plus apalutamide improves the time to radiographic progression per Prostate Cancer Working Group 3 (PCWG3) guidelines. III. To determine the time to castration-resistant prostate cancer (CRPC) between arms. IV. To determine symptomatic skeletal event free survival (SSE-FS) between arms. V. To determine the safety and tolerability of the triplet versus doublet using Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0. VI. To determine radiographic progression free survival (rPFS), and overall survival (OS) in patients by the stratification factors a) volume/timing of disease (metachronous high volume, synchronous high volume, and synchronous low volume metastases on conventional imaging) and b) tumor suppressor gene alteration status (0 versus \[vs\] 1 vs 2+) between arms. VII. To determine prostate specific antigen (PSA) 90 response rate at 6 weeks and 6 months between arms. VIII. To determine time to PSA progression by PCWG3 criteria between arms. IX. To determine objective response rate (ORR) in patients with measurable disease between arms. EXPLORATORY OBJECTIVES: I. To determine the time to worsening of physical symptoms of disease based on functional assessment of cancer therapy/National Comprehensive Cancer Network prostate cancer symptom index 17 item questionnaire (NCCN-FACT FPSI-17) between arms. II. To compare quality of life as measured by Functional Assessment of Cancer Therapy-Prostate (FACT-P) trial outcome index in patients with metastatic castrate-sensitive prostate cancer (mCSPC) who receive ADT + apalutamide + docetaxel vs ADT + apalutamide at the 24-month time point. III. To compare quality of life as measured by other scales of the FACT-P in the two arms. IV. To compare quality of life as measured by FACT-P total outcome index in the two arms at other timepoints. V. To compare pain severity and interference as measured by the Brief Pain Inventory Short Form (BPI-SF) in the two arms. VI. To compare quality-adjusted life years which accounts for survival and utility (measured by European Quality of Life Five Dimension Five Level Scale \[EQ-5D-5L\]) in the two arms. VII. To correlate baseline volume of disease on prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT) with baseline volume of disease on conventional imaging (CI). VIII. To determine if baseline PSMA-PET/CT and CI are individually and jointly associated with OS, progression-free survival (PFS), PSA90 response, and PSA \< 0.2 ng/ml after 6 months, and to estimate its clinical relevance when compared to these well characterized prognostic endpoints. IX. To correlate 6-month PSA level with the presence/absence and volume of residual disease on PSMA-PET/CT after 6 months of doublet or triplet therapy. X. To correlate the concordance of radiographic progression on CI versus PSMA-PET/CT at the time of PSA progression. XI. To determine rPFS, time to castration resistance, OS based on thresholds of volume of disease, and prostate-specific membrane antigen (PSMA) uptake (standardized uptake value \[SUV\]) based on baseline PSMA-PET/CT scan. XII. To compare rPFS, time to castration resistance, and OS between arms in patients with de novo metastatic disease having received primary directed radiation therapy. XIII. To determine rPFS, time to castration resistance, and OS correlation with PSA response at 6 weeks and 6 months. XIV. To compare the impact of treatment on aging trajectory, as measured by the change in Deficit-Accumulation Frailty Index (DAFI) from baseline, 6- and 12-months, in the two arms. OUTLINE: Patients are randomized to 1 of 2 arms. ARM 1: Patients receive ADT at the discretion of the investigator and apalutamide orally (PO) once daily (QD). Cycles repeat every 12 weeks in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo computed tomography (CT) scan or magnetic resonance imaging (MRI) and bone scan throughout the study. Patients may optionally undergo prostate-specific membrane antigen-positron emission tomography (PSMA-PET) scans and blood sample collection throughout the study. ARM 2: Patients receive ADT at the discretion of the investigator and apalutamide PO QD. Cycles repeat every 12 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive docetaxel intravenously (IV) over 1 hour every 21 days for up to 6 doses. Additionally, patients undergo CT scan or MRI and bone scan throughout the study. Patients may optionally undergo PSMA-PET scans and blood sample collection throughout the study. After completion of study treatment, patients are followed up every 6 months for up to 10 years.

Arms & interventions

  • DrugAndrogen Therapy

    Given ADT

  • DrugApalutamide

    Given PO

  • DrugDocetaxel

    Given IV

  • ProcedureComputed Tomography

    Undergo CT

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

  • ProcedureBone Scan

    Undergo Bone Scan

  • ProcedurePSMA PET Scan

    Undergo PSMA PET Scan

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

  • OtherQuestionnaire Administration

    undergo Questionnaire Administration

Outcome measures

Primary

  • Overall survival (OS)

    Will determine OS. To assess the potential OS benefit from the triplet therapy, a group sequential efficacy/futility monitoring design will be employed. The planned analyses for OS will be tested using a one-sided type 1 error rate of 0.025. An intent-to-treat approach will be used to evaluate OS between treatments. The stratified logrank test will be the primary analysis to compare OS between treatments. The Kaplan-Meier estimate will be used to evaluate the within treatment OS distributions. In addition, the proportional hazards model will be applied to assess the treatment comparison adjusting for important covariates in predicting OS.

    Time frame: From randomization to death due to any cause, assessed up to 10 years

Secondary

  • Overall Survival (OS)

    Time frame: From randomization to death due to any cause, assessed up to 10 years

  • Radiographic progression

    Time frame: From randomization to first documentation of radiographic progressive disease or death due to any cause, assessed up to 10 years

  • Castration-resistant prostate cancer (CRPC)

    Time frame: Time to prostate-specific antigen progression with serum testosterone being at castrate level < 0.50 ng/mL, or the time to progression by soft tissue/visceral lesions or time to progression by bone lesions per PCWG3 guidelines, assessed up to 10 years

  • Symptomatic skeletal event free survival (SSE-FS)

    Time frame: From randomization to first occurrence of SSE or death from any cause, assessed up to 10 years

  • Worsening of physical symptoms of disease

    Time frame: up to 10 years

  • Incidence of adverse events

    Time frame: up to 10 years

  • Radiographic progression free survival (rPFS)

    Time frame: From randomization to first documentation of radiographic progressive disease or death due to any cause, assessed up to 10 years

  • OS

    Time frame: Will determine OS in patients by the stratification factors a) timing/volume of disease 1) metachronous high volume, 2) synchronous high volume and 3) synchronous low volume metastases on conventional imaging. To assess the potential OS benefit from the

  • Prostate specific antigen (PSA) 90 response rate

    Time frame: At 6 weeks and 6 months

  • Time to PSA progression

    Time frame: From randomization to the date of PSA progression based on PCWG3 criteria, assessed up to 10 years

  • Objective response rate (ORR)

    Time frame: up to 10 years

Eligibility criteria

Sex: MaleAge: 18 Years and olderHealthy volunteers: No
Inclusion Criteria: * Documentation of disease: \* Histologically or cytologically confirmed adenocarcinoma of the prostate without small cell histology * Must have had evidence of metastatic disease (American Joint Committee on Cancer \[AJCC\] metastasis \[M\]1 disease) based on conventional CT/MRI and/or bone scan. This will be defined as: * Bone metastases detected by CT, radionuclide technetium-99 (99Tc)- methylene bisphosphonate bone scan, or MRI as defined by PCWG3 criteria; OR * Non-pelvic lymph node metastases (measurable lymph nodes above the aortic bifurcation; lymph nodes are measurable if the short axis diameter is ≥ 15 mm) detected on CT or MRI as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Subjects with regional lymph node metastases only (nodes \[N\]1, below the aortic bifurcation) will not be eligible for the study; OR * Visceral or soft tissue metastases detected on CT or MRI as defined by RECIST version 1.1. Soft tissue/visceral lesions are measurable if the long axis diameter is ≥ 10 mm * Evidence of metastatic disease by PSMA-PET only and not visible by CT, radionuclide bone scan, or MRI will not satisfy eligibility criteria * No metachronous low-volume disease (defined as recurrent metastatic disease after definitive treatment of prostate primary) and with ≤ 4 bone metastasis and no visceral metastasis on conventional imaging by CT, radionuclide 99Tc-biphosphonate bone scan, or MRI) * Next generation sequencing (NGS) results from any tissue based Clinical Laboratory Improvement Act (CLIA) test must be available at the time of registration. NGS from soft tissue or visceral lesion if available is preferred. NGS from bone or primary prostate will be accepted. Patients with failed NGS testing are not eligible * Prior treatment * ADT (luteinizing hormone-releasing hormone \[LHRH\] agonist/antagonist or orchiectomy) with or without first generation anti-androgen, or second-generation androgen receptor signaling inhibitor (ARSI) within 120 days of registration is permitted. No washout period will be needed for the first generation- androgen or ARSI prior to registration. Anti-androgen treatment is only permitted if used within 120 days of registration * No prior chemotherapy for prostate cancer * Age ≥ 18 years * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 * Absolute neutrophil count (ANC) ≥ 1,500/mm\^3 * Hemoglobin ≥ 9.0 g/dL * Platelet count ≥ 100,000/mm\^3 * Total bilirubin ≤ 1 x upper limit of normal (ULN) (Note: In subjects with Gilbert's syndrome, if total bilirubin is \> 1.5 × ULN, measure direct and indirect bilirubin and if direct bilirubin is ≤ 1 × ULN, subject may be eligible) * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate transaminase \[SGT\]) ≤ 1.5 x upper limit of normal (ULN) * Calculated (Calc.) creatinine clearance \> 30 mL/min * Serum potassium ≥ 3.5 mmol/L * Comorbid conditions * Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial * Leptomeningeal metastases: Patients with treated leptomeningeal metastases are eligible if follow-up brain imaging 30 days after central nervous system (CNS)-directed therapy shows no evidence of progression * HIV: Patients with known HIV infection on effective anti-retroviral therapy with undetectable viral load within 6 months prior to registration are eligible for this trial * Hepatitis B: For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated * Hepatitis C: Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load * No seizure or known condition that may pre-dispose to seizure (e.g. prior stroke within 1 year to randomization, brain arteriovenous malformation or condition requiring CNS surgery or radiation therapy) * Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association functional classification. To be eligible for this trial, patients should be class II or better. Any condition that in the opinion of the investigator, would preclude participation in this study. Patients with stable asymptomatic deep venous thromboembolism on stable anti-coagulation will be eligible * Hypertension: Subjects with uncontrolled hypertension as indicated by a resting systolic blood pressure (BP) \>= 160 mmHg or diastolic BP \>= 100 mmHg despite medical management are not permitted to register * Allergies: Subjects with known hypersensitivity to any of the study drugs, or excipients in the formulation of the study drugs are not permitted to register * Concomitant medications * Chronic concomitant treatment with strong inhibitors of cytochrome P450 3A4 (CYP3A4) is not allowed on this study. Patients on strong CYP3A4 inhibitors must discontinue the drug prior to registration on the study. See Section 8.1.9 for more information * Chronic concomitant treatment with strong CYP3A4 inducers is not allowed. Patients must discontinue the drug 14 days prior to the start of study treatment * Medications known to lower the seizure threshold must be discontinued or substituted prior to study entry. See Section 8.1.9 for more information * Patient agrees to use a condom (even men with vasectomies) and another effective method of birth control if having sex with a woman of childbearing potential or agrees to use a condom if having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug. Must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drug

Study locations (194)

Banner University Medical Center - Tucson

Tucson, Arizona, 85719

Recruiting
Site Public Contact · Contact
UACC-IIT@uacc.arizona.edu
Edward P. Gelmann · Principal Investigator

University of Arizona Cancer Center-North Campus

Tucson, Arizona, 85719

Recruiting
Site Public Contact · Contact
UACC-IIT@uacc.arizona.edu
Edward P. Gelmann · Principal Investigator

Kaiser Permanente Dublin

Dublin, California, 94568

Recruiting
Site Public Contact · Contact
877-642-4691
Andrea L. Harzstark · Principal Investigator

Kaiser Permanente-Fremont

Fremont, California, 94538

Recruiting
Site Public Contact · Contact
877-642-4691Kpoct@kp.org
Andrea L. Harzstark · Principal Investigator

Kaiser Permanente Fresno Orchard Plaza

Fresno, California, 93720

Recruiting
Site Public Contact · Contact
833-574-2273
Andrea L. Harzstark · Principal Investigator

UC San Diego Moores Cancer Center

La Jolla, California, 92093

Recruiting
Site Public Contact · Contact
858-822-5354cancercto@ucsd.edu
Yu-Wei Chen · Principal Investigator

Kaiser Permanente- Modesto MOB II

Modesto, California, 95356

Recruiting
Site Public Contact · Contact
877-642-4691
Andrea L. Harzstark · Principal Investigator

Kaiser Permanente-Modesto

Modesto, California, 95356

Recruiting
Site Public Contact · Contact
877-642-4691Kpoct@kp.org
Andrea L. Harzstark · Principal Investigator

Kaiser Permanente-Oakland

Oakland, California, 94611

Recruiting
Site Public Contact · Contact
877-642-4691Kpoct@kp.org
Andrea L. Harzstark · Principal Investigator

Eisenhower Medical Center

Rancho Mirage, California, 92270

Recruiting
Site Public Contact · Contact
760-834-3798
Delshad Ahmad · Principal Investigator

Kaiser Permanente-Roseville

Roseville, California, 95661

Recruiting
Site Public Contact · Contact
877-642-4691Kpoct@kp.org
Andrea L. Harzstark · Principal Investigator

Kaiser Permanente Downtown Commons

Sacramento, California, 95814

Recruiting
Site Public Contact · Contact
877-642-4691kpoct@kp.org
Andrea L. Harzstark · Principal Investigator

Kaiser Permanente-South Sacramento

Sacramento, California, 95823

Recruiting
Site Public Contact · Contact
877-642-4691Kpoct@kp.org
Andrea L. Harzstark · Principal Investigator

UC San Diego Medical Center - Hillcrest

San Diego, California, 92103

Recruiting
Site Public Contact · Contact
rhabbaba@health.ucsd.edu
Yu-Wei Chen · Principal Investigator

Kaiser Permanente-San Francisco

San Francisco, California, 94115

Recruiting
Site Public Contact · Contact
877-642-4691Kpoct@kp.org
Andrea L. Harzstark · Principal Investigator

Kaiser Permanente-Santa Teresa-San Jose

San Jose, California, 95119

Recruiting
Site Public Contact · Contact
877-642-4691Kpoct@kp.org
Andrea L. Harzstark · Principal Investigator

Kaiser Permanente San Leandro

San Leandro, California, 94577

Recruiting
Site Public Contact · Contact
877-642-4691Kpoct@kp.org
Andrea L. Harzstark · Principal Investigator

Kaiser San Rafael-Gallinas

San Rafael, California, 94903

Recruiting
Site Public Contact · Contact
877-642-4691Kpoct@kp.org
Andrea L. Harzstark · Principal Investigator

Kaiser Permanente Medical Center - Santa Clara

Santa Clara, California, 95051

Recruiting
Site Public Contact · Contact
877-642-4691Kpoct@kp.org
Andrea L. Harzstark · Principal Investigator

Kaiser Permanente-Santa Rosa

Santa Rosa, California, 95403

Recruiting
Site Public Contact · Contact
877-642-4691Kpoct@kp.org
Andrea L. Harzstark · Principal Investigator

Kaiser Permanente-South San Francisco

South San Francisco, California, 94080

Recruiting
Site Public Contact · Contact
877-642-4691Kpoct@kp.org
Andrea L. Harzstark · Principal Investigator

Kaiser Permanente-Vallejo

Vallejo, California, 94589

Recruiting
Site Public Contact · Contact
877-642-4691Kpoct@kp.org
Andrea L. Harzstark · Principal Investigator

Kaiser Permanente-Walnut Creek

Walnut Creek, California, 94596

Recruiting
Site Public Contact · Contact
877-642-4691Kpoct@kp.org
Andrea L. Harzstark · Principal Investigator

Kaiser Permanente-Franklin

Denver, Colorado, 80205

Recruiting
Site Public Contact · Contact
303-817-9295KPCOIHRClinicalResearch@kp.org
Matthew J. Eadens · Principal Investigator

Saint Mary's Hospital and Regional Medical Center

Grand Junction, Colorado, 81501

Recruiting
Site Public Contact · Contact
303-777-2663ccrp@co-cancerresearch.org
Wallace Jones · Principal Investigator

Kaiser Permanente-Rock Creek

Lafayette, Colorado, 80026

Recruiting
Site Public Contact · Contact
303-817-9295KPCOIHRClinicalResearch@kp.org
Matthew J. Eadens · Principal Investigator

Kaiser Permanente-Lone Tree

Lone Tree, Colorado, 80124

Recruiting
Site Public Contact · Contact
303-817-9295KPCOIHRClinicalResearch@kp.org
Matthew J. Eadens · Principal Investigator

Bayhealth Hospital Kent Campus

Dover, Delaware, 19901

Active Not Recruiting

Bayhealth Hospital Sussex Campus

Milford, Delaware, 19963

Active Not Recruiting

MedStar Georgetown University Hospital

Washington D.C., District of Columbia, 20007

Recruiting
Site Public Contact · Contact
202-444-2223
Suthee Rapisuwon · Principal Investigator

MedStar Washington Hospital Center

Washington D.C., District of Columbia, 20010

Recruiting
Site Public Contact · Contact
202-877-8839
Suthee Rapisuwon · Principal Investigator

Malcom Randall Veterans Administration Medical Center

Gainesville, Florida, 32610

Recruiting
Site Public Contact · Contact
352-273-8675trials@cancer.ufl.edu
Jess DeLaune · Principal Investigator

Kaiser Permanente Moanalua Medical Center

Honolulu, Hawaii, 96819

Recruiting
Site Public Contact · Contact
808-432-5195shelley.a.clark@kp.org
Andrea L. Harzstark · Principal Investigator

Saint Luke's Cancer Institute - Boise

Boise, Idaho, 83712

Recruiting
Site Public Contact · Contact
208-381-2774eslinget@slhs.org
Alison K. Conlin · Principal Investigator

Kootenai Health - Coeur d'Alene

Coeur d'Alene, Idaho, 83814

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Saint Luke's Cancer Institute - Fruitland

Fruitland, Idaho, 83619

Recruiting
Site Public Contact · Contact
208-381-2774eslinget@slhs.org
Alison K. Conlin · Principal Investigator

Saint Luke's Cancer Institute - Meridian

Meridian, Idaho, 83642

Recruiting
Site Public Contact · Contact
208-381-2774eslinget@slhs.org
Alison K. Conlin · Principal Investigator

Saint Luke's Cancer Institute - Nampa

Nampa, Idaho, 83687

Recruiting
Site Public Contact · Contact
208-381-2774eslinget@slhs.org
Alison K. Conlin · Principal Investigator

Kootenai Clinic Cancer Services - Post Falls

Post Falls, Idaho, 83854

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Kootenai Clinic Cancer Services - Sandpoint

Sandpoint, Idaho, 83864

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Illinois CancerCare-Bloomington

Bloomington, Illinois, 61704

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Canton

Canton, Illinois, 61520

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Carthage

Carthage, Illinois, 62321

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Centralia Oncology Clinic

Centralia, Illinois, 62801

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

Rush MD Anderson Cancer Center

Chicago, Illinois, 60612

Recruiting
Site Public Contact · Contact
312-226-2371Cancer_Studies@rush.edu
Thomas C. Westbrook · Principal Investigator

University of Illinois

Chicago, Illinois, 60612

Recruiting
Site Public Contact · Contact
312-355-3046
Karine Tawagi · Principal Investigator

Carle at The Riverfront

Danville, Illinois, 61832

Recruiting
Site Public Contact · Contact
800-446-5532Research@Carle.com
Kendrith M. Rowland · Principal Investigator

Cancer Care Specialists of Illinois - Decatur

Decatur, Illinois, 62526

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

Decatur Memorial Hospital

Decatur, Illinois, 62526

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Dixon

Dixon, Illinois, 61021

Recruiting
Site Public Contact · Contact
815-285-7800
Bryan A. Faller · Principal Investigator

Carle Physician Group-Effingham

Effingham, Illinois, 62401

Recruiting
Site Public Contact · Contact
800-446-5532Research@carle.com
Kendrith M. Rowland · Principal Investigator

Crossroads Cancer Center

Effingham, Illinois, 62401

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Eureka

Eureka, Illinois, 61530

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Galesburg

Galesburg, Illinois, 61401

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Kewanee Clinic

Kewanee, Illinois, 61443

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Macomb

Macomb, Illinois, 61455

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Carle Physician Group-Mattoon/Charleston

Mattoon, Illinois, 61938

Recruiting
Site Public Contact · Contact
800-446-5532Research@carle.com
Kendrith M. Rowland · Principal Investigator

Carle BroMenn Medical Center

Normal, Illinois, 61761

Recruiting
Site Public Contact · Contact
800-446-5532Research@Carle.com
Kendrith M. Rowland · Principal Investigator

Carle Cancer Institute Normal

Normal, Illinois, 61761

Recruiting
Site Public Contact · Contact
800-446-5532Research@Carle.com
Kendrith M. Rowland · Principal Investigator

Cancer Care Center of O'Fallon

O'Fallon, Illinois, 62269

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

HSHS Saint Elizabeth's Hospital

O'Fallon, Illinois, 62269

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Ottawa Clinic

Ottawa, Illinois, 61350

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Pekin

Pekin, Illinois, 61554

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Peoria

Peoria, Illinois, 61615

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Peru

Peru, Illinois, 61354

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Princeton

Princeton, Illinois, 61356

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Memorial Hospital East

Shiloh, Illinois, 62269

Recruiting
Site Public Contact · Contact
314-747-9912dschwab@wustl.edu
Eric M. Knoche · Principal Investigator

Southern Illinois University School of Medicine

Springfield, Illinois, 62702

Recruiting
Site Public Contact · Contact
217-545-7929
Bryan A. Faller · Principal Investigator

Springfield Clinic

Springfield, Illinois, 62702

Recruiting
Site Public Contact · Contact
800-444-7541
Bryan A. Faller · Principal Investigator

Springfield Memorial Hospital

Springfield, Illinois, 62781

Recruiting
Site Public Contact · Contact
217-528-7541pallante.beth@mhsil.com
Bryan A. Faller · Principal Investigator

Carle Cancer Center

Urbana, Illinois, 61801

Recruiting
Site Public Contact · Contact
800-446-5532Research@carle.com
Kendrith M. Rowland · Principal Investigator

Illinois CancerCare - Washington

Washington, Illinois, 61571

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Mary Greeley Medical Center

Ames, Iowa, 50010

Recruiting
Site Public Contact · Contact
515-956-4132
Joseph J. Merchant · Principal Investigator

McFarland Clinic - Ames

Ames, Iowa, 50010

Recruiting
Site Public Contact · Contact
515-239-4734ksoder@mcfarlandclinic.com
Joseph J. Merchant · Principal Investigator

McFarland Clinic - Boone

Boone, Iowa, 50036

Suspended

Mercy Hospital

Cedar Rapids, Iowa, 52403

Recruiting
Site Public Contact · Contact
319-365-4673
Deborah W. Wilbur · Principal Investigator

Oncology Associates at Mercy Medical Center

Cedar Rapids, Iowa, 52403

Recruiting
Site Public Contact · Contact
319-363-2690
Deborah W. Wilbur · Principal Investigator

McFarland Clinic - Trinity Cancer Center

Fort Dodge, Iowa, 50501

Recruiting
Site Public Contact · Contact
515-956-4132
Joseph J. Merchant · Principal Investigator

McFarland Clinic - Jefferson

Jefferson, Iowa, 50129

Suspended

McFarland Clinic - Marshalltown

Marshalltown, Iowa, 50158

Recruiting
Site Public Contact · Contact
515-956-4132
Joseph J. Merchant · Principal Investigator

HaysMed

Hays, Kansas, 67601

Recruiting
Site Public Contact · Contact
785-623-5774
Elizabeth M. Wulff · Principal Investigator

Lawrence Memorial Hospital

Lawrence, Kansas, 66044

Recruiting
Site Public Contact · Contact
785-505-2800Stephanie.Norris@LMH.ORG
Elizabeth M. Wulff · Principal Investigator

The University of Kansas Cancer Center - Olathe

Olathe, Kansas, 66061

Recruiting
Site Public Contact · Contact
913-588-1569OlatheCCResearch@kumc.edu
Elizabeth M. Wulff · Principal Investigator

University of Kansas Cancer Center-Overland Park

Overland Park, Kansas, 66210

Recruiting
Site Public Contact · Contact
913-588-3671KUCC_Navigation@kumc.edu
Elizabeth M. Wulff · Principal Investigator

Salina Regional Health Center

Salina, Kansas, 67401

Recruiting
Site Public Contact · Contact
785-452-7038mleepers@srhc.com
Elizabeth M. Wulff · Principal Investigator

University of Kansas Health System Saint Francis Campus

Topeka, Kansas, 66606

Recruiting
Site Public Contact · Contact
785-295-8000
Elizabeth M. Wulff · Principal Investigator

University of Kansas Hospital-Westwood Cancer Center

Westwood, Kansas, 66205

Recruiting
Site Public Contact · Contact
913-588-3671KUCC_Navigation@kumc.edu
Elizabeth M. Wulff · Principal Investigator

Trinity Health IHA Medical Group Hematology Oncology - Brighton

Brighton, Michigan, 48114

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Christopher M. Reynolds · Principal Investigator

Trinity Health IHA Medical Group Hematology Oncology - Canton

Canton, Michigan, 48188

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Christopher M. Reynolds · Principal Investigator

Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital

Chelsea, Michigan, 48118

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Christopher M. Reynolds · Principal Investigator

OSF Saint Francis Hospital and Medical Group

Escanaba, Michigan, 49829

Recruiting
Site Public Contact · Contact
920-433-8889WI_research_admin@hshs.org
Anthony J. Jaslowski · Principal Investigator

Genesys Hurley Cancer Institute

Flint, Michigan, 48503

Recruiting
Site Public Contact · Contact
810-762-8038wstrong@ghci.org
Christopher M. Reynolds · Principal Investigator

Hurley Medical Center

Flint, Michigan, 48503

Recruiting
Site Public Contact · Contact
810-762-8038wstrong@ghci.org
Christopher M. Reynolds · Principal Investigator

University of Michigan Health - Sparrow Lansing

Lansing, Michigan, 48912

Recruiting
Site Public Contact · Contact
517-364-3712harsha.trivedi@umhsparrow.org
Christopher M. Reynolds · Principal Investigator

Trinity Health Saint Mary Mercy Livonia Hospital

Livonia, Michigan, 48154

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Christopher M. Reynolds · Principal Investigator

Trinity Health Saint Joseph Mercy Oakland Hospital

Pontiac, Michigan, 48341

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Christopher M. Reynolds · Principal Investigator

Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus

Ypsilanti, Michigan, 48197

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Christopher M. Reynolds · Principal Investigator

Sanford Joe Lueken Cancer Center

Bemidji, Minnesota, 56601

Recruiting
Site Public Contact · Contact
218-333-5000OncologyClinicalTrialsFargo@sanfordhealth.org
Daniel Almquist · Principal Investigator

Coborn Cancer Center at Saint Cloud Hospital

Saint Cloud, Minnesota, 56303

Recruiting
Site Public Contact · Contact
877-229-4907coborncancercenter@centracare.com
Donald J. Jurgens · Principal Investigator

Saint Francis Medical Center

Cape Girardeau, Missouri, 63703

Recruiting
Site Public Contact · Contact
573-334-2230sfmc@sfmc.net
Bryan A. Faller · Principal Investigator

Siteman Cancer Center at Saint Peters Hospital

City of Saint Peters, Missouri, 63376

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Eric M. Knoche · Principal Investigator

Siteman Cancer Center at West County Hospital

Creve Coeur, Missouri, 63141

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Eric M. Knoche · Principal Investigator

University Health Truman Medical Center

Kansas City, Missouri, 64108

Recruiting
Site Public Contact · Contact
816-404-4375
Elizabeth M. Wulff · Principal Investigator

University of Kansas Cancer Center - Briarcliff

Kansas City, Missouri, 64116

Recruiting
Site Public Contact · Contact
913-588-3671
Elizabeth M. Wulff · Principal Investigator

University of Kansas Cancer Center - North

Kansas City, Missouri, 64154

Recruiting
Site Public Contact · Contact
913-588-3671KUCC_Navigation@kumc.edu
Elizabeth M. Wulff · Principal Investigator

University of Kansas Cancer Center - Lee's Summit

Lee's Summit, Missouri, 64064

Recruiting
Site Public Contact · Contact
913-588-3671KUCC_Navigation@kumc.edu
Elizabeth M. Wulff · Principal Investigator

Washington University School of Medicine

St Louis, Missouri, 63110

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Eric M. Knoche · Principal Investigator

Mercy Hospital South

St Louis, Missouri, 63128

Recruiting
Site Public Contact · Contact
314-525-6042Danielle.Werle@mercy.net
Jay W. Carlson · Principal Investigator

Siteman Cancer Center-South County

St Louis, Missouri, 63129

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Eric M. Knoche · Principal Investigator

Siteman Cancer Center at Christian Hospital

St Louis, Missouri, 63136

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Eric M. Knoche · Principal Investigator

Mercy Hospital Saint Louis

St Louis, Missouri, 63141

Recruiting
Site Public Contact · Contact
314-251-7066
Jay W. Carlson · Principal Investigator

Community Hospital of Anaconda

Anaconda, Montana, 59711

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Billings Clinic Cancer Center

Billings, Montana, 59101

Recruiting
Site Public Contact · Contact
800-996-2663research@billingsclinic.org
John M. Schallenkamp · Principal Investigator

Saint Vincent Frontier Cancer Center

Billings, Montana, 59102

Recruiting
Site Public Contact · Contact
800-648-6274
Wallace Jones · Principal Investigator

Bozeman Health Deaconess Hospital

Bozeman, Montana, 59715

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Benefis Sletten Cancer Institute

Great Falls, Montana, 59405

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Logan Health Medical Center

Kalispell, Montana, 59901

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Community Medical Center

Missoula, Montana, 59804

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Memorial Sloan Kettering Basking Ridge

Basking Ridge, New Jersey, 07920

Recruiting
Site Public Contact · Contact
212-639-7592
Kristine P. Lacuna · Principal Investigator

Jefferson Cherry Hill Hospital

Cherry Hill, New Jersey, 08002

Recruiting
Site Public Contact · Contact
215-600-9151ONCTrialNow@jefferson.edu
Kevin K. Zarrabi · Principal Investigator

Memorial Sloan Kettering Monmouth

Middletown, New Jersey, 07748

Recruiting
Site Public Contact · Contact
212-639-7592
Kristine P. Lacuna · Principal Investigator

Memorial Sloan Kettering Bergen

Montvale, New Jersey, 07645

Recruiting
Site Public Contact · Contact
212-639-7592
Kristine P. Lacuna · Principal Investigator

Sidney Kimmel Cancer Center Washington Township

Sewell, New Jersey, 08080

Recruiting
Site Public Contact · Contact
215-600-9151ONCTrialNow@jefferson.edu
Kevin K. Zarrabi · Principal Investigator

Roswell Park Cancer Institute

Buffalo, New York, 14263

Recruiting
Site Public Contact · Contact
800-767-9355askroswell@roswellpark.org
Ellis G. Levine · Principal Investigator

Memorial Sloan Kettering Commack

Commack, New York, 11725

Recruiting
Site Public Contact · Contact
212-639-7592
Kristine P. Lacuna · Principal Investigator

Guthrie Cortland Memorial Hospital

Cortland, New York, 13045

Recruiting
Site Public Contact · Contact
607-756-3130
Alina Basnet · Principal Investigator

Memorial Sloan Kettering Westchester

Harrison, New York, 10604

Recruiting
Site Public Contact · Contact
212-639-7592
Kristine P. Lacuna · Principal Investigator

Mount Sinai Hospital

New York, New York, 10029

Recruiting
Site Public Contact · Contact
212-824-7309CCTO@mssm.edu
Eric J. Miller · Principal Investigator

Memorial Sloan Kettering Cancer Center

New York, New York, 10065

Recruiting
Site Public Contact · Contact
212-639-7592
Kristine P. Lacuna · Principal Investigator

Stony Brook University Medical Center

Stony Brook, New York, 11794

Recruiting
Site Public Contact · Contact
800-862-2215
Judy Huang · Principal Investigator

Memorial Sloan Kettering Nassau

Uniondale, New York, 11553

Recruiting
Site Public Contact · Contact
212-639-7592
Kristine P. Lacuna · Principal Investigator

Duke University Medical Center

Durham, North Carolina, 27710

Recruiting
Site Public Contact · Contact
888-275-3853
Hannah D. McManus · Principal Investigator

FirstHealth of the Carolinas-Moore Regional Hospital

Pinehurst, North Carolina, 28374

Recruiting
Site Public Contact · Contact
910-715-3500jcwilliams@firsthealth.org
Charles S. Kuzma · Principal Investigator

Sanford Bismarck Medical Center

Bismarck, North Dakota, 58501

Recruiting
Site Public Contact · Contact
701-323-5760OncologyClinicalTrialsFargo@sanfordhealth.org
Daniel Almquist · Principal Investigator

Sanford Broadway Medical Center

Fargo, North Dakota, 58122

Recruiting
Site Public Contact · Contact
701-323-5760OncologyClinicalTrialsFargo@sanfordhealth.org
Daniel Almquist · Principal Investigator

Sanford Roger Maris Cancer Center

Fargo, North Dakota, 58122

Recruiting
Site Public Contact · Contact
701-234-6161OncologyClinicalTrialsFargo@sanfordhealth.org
Daniel Almquist · Principal Investigator

Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210

Recruiting
Site Public Contact · Contact
800-293-5066Jamesline@osumc.edu
Lingbin Meng · Principal Investigator

ProMedica Flower Hospital

Sylvania, Ohio, 43560

Recruiting
Site Public Contact · Contact
419-824-1842PCIOncResearch@promedica.org
Jeffrey H. Muler · Principal Investigator

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104

Recruiting
Site Public Contact · Contact
405-271-8777ou-clinical-trials@ouhsc.edu
Adanma Anji Ayanambakkam Attanathi · Principal Investigator

Saint Vincent Hospital

Erie, Pennsylvania, 16544

Recruiting
Site Public Contact · Contact
814-452-5000
Shifeng S. Mao · Principal Investigator

Jefferson Hospital

Jefferson Hills, Pennsylvania, 15025

Recruiting
Site Public Contact · Contact
412-359-3043ddefazio@wpahs.org
Shifeng S. Mao · Principal Investigator

Forbes Hospital

Monroeville, Pennsylvania, 15146

Recruiting
Site Public Contact · Contact
412-858-7746
Shifeng S. Mao · Principal Investigator

Allegheny Valley Hospital

Natrona Heights, Pennsylvania, 15065

Recruiting
Site Public Contact · Contact
Dawnmarie.DeFazio@ahn.org
Shifeng S. Mao · Principal Investigator

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, 19107

Recruiting
Site Public Contact · Contact
215-600-9151ONCTrialNow@jefferson.edu
Kevin K. Zarrabi · Principal Investigator

Jefferson Torresdale Hospital

Philadelphia, Pennsylvania, 19114

Recruiting
Site Public Contact · Contact
215-600-9151ONCTrialNow@jefferson.edu
Kevin K. Zarrabi · Principal Investigator

Jefferson Methodist Hospital

Philadelphia, Pennsylvania, 19148

Suspended

Allegheny General Hospital

Pittsburgh, Pennsylvania, 15212

Recruiting
Site Public Contact · Contact
877-284-2000
Shifeng S. Mao · Principal Investigator

West Penn Hospital

Pittsburgh, Pennsylvania, 15224

Recruiting
Site Public Contact · Contact
412-578-5000
Shifeng S. Mao · Principal Investigator

Guthrie Medical Group PC-Robert Packer Hospital

Sayre, Pennsylvania, 18840

Recruiting
Site Public Contact · Contact
800-836-0388
Joyson Poulose · Principal Investigator

Wexford Health and Wellness Pavilion

Wexford, Pennsylvania, 15090

Recruiting
Site Public Contact · Contact
Dawnmarie.DeFazio@ahn.org
Shifeng S. Mao · Principal Investigator

Asplundh Cancer Pavilion

Willow Grove, Pennsylvania, 19090

Recruiting
Site Public Contact · Contact
215-600-9151ONCTrialNow@jefferson.edu
Kevin K. Zarrabi · Principal Investigator

Saint Francis Hospital

Greenville, South Carolina, 29601

Recruiting
Site Public Contact · Contact
864-603-6234Heather_Rich@bshsi.org
Stephen H. Dyar · Principal Investigator

Saint Francis Cancer Center

Greenville, South Carolina, 29607

Recruiting
Site Public Contact · Contact
864-603-6234Heather_Rich@bshsi.org
Stephen H. Dyar · Principal Investigator

Self Regional Healthcare

Greenwood, South Carolina, 29646

Recruiting
Site Public Contact · Contact
864-725-4771nmcgaha@selfregional.org
Albert C. Lockhart · Principal Investigator

Rapid City Regional Hospital

Rapid City, South Dakota, 57701

Recruiting
Site Public Contact · Contact
605-755-2370research@monument.health
Abdel-Ghani Azzouqa · Principal Investigator

Sanford Cancer Center Oncology Clinic

Sioux Falls, South Dakota, 57104

Recruiting
Site Public Contact · Contact
605-312-3320OncologyClinicTrialsSF@sanfordhealth.org
Daniel Almquist · Principal Investigator

Sanford USD Medical Center - Sioux Falls

Sioux Falls, South Dakota, 57117-5134

Recruiting
Site Public Contact · Contact
605-312-3320OncologyClinicalTrialsSF@SanfordHealth.org
Daniel Almquist · Principal Investigator

UT Southwestern Simmons Cancer Center - RedBird

Dallas, Texas, 75237

Recruiting
Site Public Contact · Contact
214-648-7097canceranswerline@utsouthwestern.edu
Qian Qin · Principal Investigator

UT Southwestern/Simmons Cancer Center-Dallas

Dallas, Texas, 75390

Recruiting
Site Public Contact · Contact
214-648-7097canceranswerline@UTSouthwestern.edu
Qian Qin · Principal Investigator

UT Southwestern/Simmons Cancer Center-Fort Worth

Fort Worth, Texas, 76104

Recruiting
Site Public Contact · Contact
214-648-7097canceranswerline@UTSouthwestern.edu
Qian Qin · Principal Investigator

UT Southwestern Clinical Center at Richardson/Plano

Richardson, Texas, 75080

Recruiting
Site Public Contact · Contact
972-669-7044Suzanne.cole@utsouthwestern.edu
Qian Qin · Principal Investigator

Intermountain Medical Center

Murray, Utah, 84107

Recruiting
Site Public Contact · Contact
801-507-3950officeofresearch@imail.org
Wallace Jones · Principal Investigator

LDS Hospital

Salt Lake City, Utah, 84143

Recruiting
Site Public Contact · Contact
801-408-1347officeofresearch@imail.org
Wallace Jones · Principal Investigator

Saint George Regional Medical Center

St. George, Utah, 84770

Recruiting
Site Public Contact · Contact
833-321-3332officeofresearch@imail.org
Wallace Jones · Principal Investigator

Central Vermont Medical Center/National Life Cancer Treatment

Berlin Corners, Vermont, 05602

Recruiting
Site Public Contact · Contact
802-225-5400
Rahul Anil · Principal Investigator

University of Vermont Medical Center

Burlington, Vermont, 05401

Recruiting
Site Public Contact · Contact
802-656-4101rpo@uvm.edu
Rahul Anil · Principal Investigator

University of Vermont and State Agricultural College

Burlington, Vermont, 05405

Recruiting
Site Public Contact · Contact
802-656-8990rpo@uvm.edu
Rahul Anil · Principal Investigator

Hematology Oncology Associates of Fredericksburg Inc

Fredericksburg, Virginia, 22408

Recruiting
Site Public Contact · Contact
540-371-0079cvaughn@hoafredericksburg.com
Asit K. Paul · Principal Investigator

VCU Massey Cancer Center at Stony Point

Richmond, Virginia, 23235

Recruiting
Site Public Contact · Contact
ctoclinops@vcu.edu
Asit K. Paul · Principal Investigator

VCU Massey Comprehensive Cancer Center

Richmond, Virginia, 23298

Recruiting
Site Public Contact · Contact
804-628-6430CTOclinops@vcu.edu
Asit K. Paul · Principal Investigator

VCU Health Tappahannock Hospital

Tappahannock, Virginia, 22560

Recruiting
Site Public Contact · Contact
klcampbell@vcu.edu
Asit K. Paul · Principal Investigator

West Virginia University Charleston Division

Charleston, West Virginia, 25304

Recruiting
Site Public Contact · Contact
304-388-9944
Kok Hoe Chan · Principal Investigator

ThedaCare Regional Cancer Center

Appleton, Wisconsin, 54911

Recruiting
Site Public Contact · Contact
920-364-3604ResearchDept@thedacare.org
Joyce Philip · Principal Investigator

Ascension Saint Elizabeth Hospital

Appleton, Wisconsin, 54915

Recruiting
Site Public Contact · Contact
AWRI.inquiry@ascension.org
Kamal Kant Singh Abbi · Principal Investigator

Ascension Southeast Wisconsin Hospital - Elmbrook Campus

Brookfield, Wisconsin, 53045

Recruiting
Site Public Contact · Contact
AWRI.Inquiry@Ascension.org
Kamal Kant Singh Abbi · Principal Investigator

Ascension Calumet Hospital

Chilton, Wisconsin, 53014

Recruiting
Site Public Contact · Contact
AWRI.inquiry@ascension.org
Kamal Kant Singh Abbi · Principal Investigator

Ascension Saint Francis - Reiman Cancer Center

Franklin, Wisconsin, 53132

Recruiting
Site Public Contact · Contact
AWRI.Inquiry@Ascension.org
Kamal Kant Singh Abbi · Principal Investigator

Saint Vincent Hospital Cancer Center Green Bay

Green Bay, Wisconsin, 54301

Recruiting
Site Public Contact · Contact
920-433-8889WI_research_admin@hshs.org
Anthony J. Jaslowski · Principal Investigator

Saint Vincent Hospital Cancer Center at Saint Mary's

Green Bay, Wisconsin, 54303

Recruiting
Site Public Contact · Contact
920-433-8889wi_research_admin@hshs.org
Anthony J. Jaslowski · Principal Investigator

William S Middleton VA Medical Center

Madison, Wisconsin, 53705

Recruiting
Site Public Contact · Contact
608-256-1901
David Kosoff · Principal Investigator

Froedtert Menomonee Falls Hospital

Menomonee Falls, Wisconsin, 53051

Recruiting
Site Public Contact · Contact
262-257-5100
Deepak Kilari · Principal Investigator

Ascension Columbia Saint Mary's Hospital Ozaukee

Mequon, Wisconsin, 53097

Recruiting
Site Public Contact · Contact
AWRI.Inquiry@Ascension.org
Kamal Kant Singh Abbi · Principal Investigator

Ascension Columbia Saint Mary's Hospital - Milwaukee

Milwaukee, Wisconsin, 53211

Recruiting
Site Public Contact · Contact
AWRI.Inquiry@Ascension.org
Kamal Kant Singh Abbi · Principal Investigator

Medical College of Wisconsin

Milwaukee, Wisconsin, 53226

Recruiting
Site Public Contact · Contact
414-805-3666
Deepak Kilari · Principal Investigator

Froedtert and MCW Moorland Reserve Health Center

New Berlin, Wisconsin, 53151

Recruiting
Site Public Contact · Contact
414-805-0505
Deepak Kilari · Principal Investigator

Drexel Town Square Health Center

Oak Creek, Wisconsin, 53154

Recruiting
Site Public Contact · Contact
414-805-0505
Deepak Kilari · Principal Investigator

Saint Vincent Hospital Cancer Center at Oconto Falls

Oconto Falls, Wisconsin, 54154

Recruiting
Site Public Contact · Contact
920-433-8889WI_research_admin@hshs.org
Anthony J. Jaslowski · Principal Investigator

Ascension Mercy Hospital

Oshkosh, Wisconsin, 54904

Recruiting
Site Public Contact · Contact
AWRI.inquiry@ascension.org
Kamal Kant Singh Abbi · Principal Investigator

Ascension All Saints Hospital

Racine, Wisconsin, 53405

Recruiting
Site Public Contact · Contact
AWRI.Inquiry@Ascension.org
Kamal Kant Singh Abbi · Principal Investigator

Saint Vincent Hospital Cancer Center at Sheboygan

Sheboygan, Wisconsin, 53081

Recruiting
Site Public Contact · Contact
920-433-8889wi_research_admin@hshs.org
Anthony J. Jaslowski · Principal Investigator

Sheboygan Physicians Group

Sheboygan, Wisconsin, 53081

Recruiting
Site Public Contact · Contact
920-433-8889wi_research_admin@hshs.org
Anthony J. Jaslowski · Principal Investigator

Saint Vincent Hospital Cancer Center at Sturgeon Bay

Sturgeon Bay, Wisconsin, 54235-1495

Recruiting
Site Public Contact · Contact
920-433-8889wi_research_admin@hshs.org
Anthony J. Jaslowski · Principal Investigator

Ascension Medical Group Southeast Wisconsin - Mayfair Road

Wauwatosa, Wisconsin, 53226

Recruiting
Site Public Contact · Contact
AWRI.Inquiry@Ascension.org
Kamal Kant Singh Abbi · Principal Investigator

Froedtert West Bend Hospital/Kraemer Cancer Center

West Bend, Wisconsin, 53095

Recruiting
Site Public Contact · Contact
414-805-0505
Deepak Kilari · Principal Investigator